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mean age at baseline was 54  9; 81 % of the patients are male. The average number
of anti-hypertensive medications at baseline was 5.4. The majority (72%) of patients
were on spironolactone at baseline. 50% of patients had changes to their medications
in response to BP changes during the 6 month follow-up period. Mean ofﬁce SBP was
16718 mmHg and mean ambulatory SBP was 15714 mmHg at baseline. Of re-
sponders, the mean decrease in ofﬁce SBP at 6months was -4125 and the mean
decrease in ambulatory SBP was -2722 at 6 months. At 1 month, MSNA decreased
by 17%; the decrease in MSNA correlated with a decrease in BP 10 mmHg in 4 of
5 patients. The most commonly reported adverse event was procedural-related pain.
There have been no reports of new onset renal artery stenosis.
Conclusions: The REALISE trial demonstrates that blood pressure can be safely
reduced in patients with moderate resistant hypertension. Ultrasound renal denervation
may provide beneﬁt in a subset of patients despite active on-going medical
management.
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Background: Despite the widely discussed unfavorable outcome of the Symplici-
tyTM HTN 3 trial, several independent trials and registries have shown a blood
pressure (BP) lowering effect in the majority of patients treated with a renal dener-
vation (RDN) device. So far, current available data are almost entirely based on the
SymplictyTM Flex System, a second-generation RDN device. Although well estab-
lished and approved, it revealed several limitations like high time consumption, high
rigidity and often a more or less random ablation pattern. The next generation Sym-
plicityTM Spyral device has been designed to overcome many of these shortcomings
by using multiple electrodes strung on a helical shaped catheter. However, the
question about the effectiveness of the new system still remains.
Methods: Our study carefully investigated the ABPM response to RDN in a cohort
of 29 consecutively treated patients with resistant hypertension using the Spyral
device. Baseline values included a mean age of 67 9.8 years, BMI of 31.3  4.4
Kg/m2, 48% women, 56% diabetic, 29% coronary artery disease and 5.4 1.2
antihypertensive medications. A 24h BP monitoring was recorded in every patient
24h before as well as 24h and 3 months after RDN. BP readings were then averaged
according to daytime (7:00am-22:00pm), nighttime (22:00pm-7:00am) and 24 hours
intervals. All data were statistically analyzed using mixed models with repeated
measurements.
Results: In treated patients mean averaged systolic 24h BP was reduced by 14.54.6
mm Hg (p< 0.005; n 29) during the ﬁrst 24 hours. A similar effect on diastolic BP was
observed: 4.92.26 mmHg (p< 0.05). First analyses of 17 patients reaching the 3
months follow-up visit reveal a sustained systolic (7.32.39 mm Hg, p< 0.05) as well
as diastolic (4.84.46 mm Hg, p< 0.05) ABPM reduction, without further decrease –
on the contrary a slight relapse to higher BP was seen.
Conclusions: Using the multi-electrode SymplicityTM Spyral renal denervation de-
vice did not only improved steerability, ablation pattern and procedure time. It also
seems to show a signiﬁcant immediate as well as persisting reduction of systolic and
diastolic ABPM.
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Background: Ethanol (EtOH)-induced renal sympathetic denervation (RDN) has
been described. We compare the results of percutaneous vs. endovascular infusion of
EtOH.
Methods: MR-guided injection of 5 or 10 ml of EtOH per renal artery to the peri-
arterial space was performed in pigs, with 4-week renal norepinephrine (NE) and
histopathology data. In the same model, the Peregrine System was used to infuse
0.15, 0.30 or 0.60 ml of EtOH to the peri-vascular space of each renal artery. His-
topathology, NE assay and immunostaining were performed at 2 weeks and 3 months.
In a clinical setting, a CT-guided injection of EtOH (10 ml) was reported, and a safety
and feasibility study (18 patients) is ongoing with the Peregrine System (0.30 ml
EtOH).
Results: In pigs, 5 or 10 ml MR-guided EtOH injections yielded NE reductions of 0%
and 53% vs. controls. The 5 ml EtOH produced no changes in renal nerve histology.
The 10 ml injection resulted in neural degeneration, perineural ﬁbrosis; hydro-
nephrosis and kidney adhesions were observed. By comparison, pigs treated with
micro-doses (endovascular) of EtOH, renal NE, neuroﬁlament protein and tyrosine
hydroxylase were all reduced in a dose-dependent manner, and circumferential
sympathetic nerve injury (2–10 mm depth from intima) was observed at all doses.
Renal NE dropped by 58%, 78% and 88%. No signiﬁcant vascular wall changes or
other systemic or anatomic pathologies were reported. The patient treated with CT-
guided injection of EtOH (10 ml) ofﬁce blood pressure (OBP) and ABPM were
lowered by 29/14 of 15/8, respectively, at 4 weeks, with no adverse anatomical
changes. No adverse events and either no pain or transient pain (< 2 min) were
observed with the Peregrine System using 0.3 ml EtOH (18 patients). At 4 weeks, theJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/HyOBP dropped an average of 27/11, while antihypertensive medications were reduced
from 3.2 to 2.1.
Conclusions: EtOH delivery into the periarterial space appears to be safe and feasible
for RDN. In preclinical testing, micro-volumes delivered via a specialized endovas-
cular catheter enabled a superior treatment than a percutaneous technique. The ob-
servations of minimal pain, safety and early efﬁcacy with this approach in a clinical
setting, are encouraging.TCT-420
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Background: Catheter-based renal artery denervation therapy has become established
as a therapeutic option in patients with resistant hypertension. We further investigated
the safety and performance of the next generation EnligHTN Renal Denervation
System (St. Jude Medical) in patients with drug-resistant hypertension.
Methods: The EnligHTN Renal Artery Ablation Catheter has 4 electrodes attached on
a basket mounted at the tip of the catheter. The next generation EnligHTN RF
Ablation Generator utilizes a novel algorithm for the delivery of 1 minute of radio-
frequency energy, optimized for simultaneous delivery of therapy through all 4
electrodes, with an interactive, intuitive user interface. Renal denervation was per-
formed on 39 patients across 6 centers meeting the following inclusion criteria: 18-80
years of age, a systolic BP 160 mmHg, an average daytime systolic ambulatory BP
135 mmHg, on three or more antihypertensive agents (including a diuretic). Renal
artery CT angiography was repeated at 6 months in all patients.
Results: To date 37/38 patients have completed 6-months of follow-up post proce-
dure. No serious device or procedure related adverse events have been observed as
adjudicated by an independent Clinical Events Committee. There were no clinically
signiﬁcant changes in renal function through 6-months as observed in eGFR, serum
creatinine, cystatin C, or urine albumin-to-creatinine ratio. 6-month ofﬁce (and
24 hour ambulatory) BP reductions from baseline were -25.2/-7.3 (-8.2/-2.0) mmHg,
which were statistically signiﬁcant except for the ambulatory diastolic reduction.
Renal artery denervation procedures were performed successfully in all patients, with
an average of 4.33 ablation sets and 15.85 ablations performed per patient. The mean
total ablation catheter insertion-to-removal time was 22.38 min and mean ablation
time was 4.33 min per patient.
Conclusions: Accumulated 12-month results from all sites will be presented. After
6-months follow-up in this ﬁrst-in-human study, we conclude that data demonstrates
the next generation EnligHTN Renal Denervation System continues to be safe, rapid,
and effective in the treatment of patients with drug-resistant, uncontrolled
hypertension.TCT-421
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Background: Renal denervation is a emerging treatment in patients with resistant
arterial hypertension. Neurohromonal activation (catecholaminergic and renin angio-
tensin aldosterone systems) play an important role in hypertensive patients; B-type
cardiac natriuretic peptides have been demonstrated as useful biomarkers of both
neurohormonal activation and cardiovascular overload.
Aim: To investigate effects of renal denervation on biomarkers of neurohormonal
activation and NT-proBNP serum values.
Methods: 6 patients with resistant hypertension (mean value >140/90 mmHg at
24 hours blood pressure monitoring despite use of three or more antihypertensive
medications) underwent renal denervation. Norepineprhine (NE), plasma renin ac-
tivity (PRA), aldosterone (A) and NT-proBNP were collected at baseline (B), 1 day
(1D) and 1 month (1M) after the procedure. Patients underwent 24 hours blood
pressure monitoring at B, 1D and 1M after the procedure. Any change in antihyper-
tensive medications was made after the procedure.
Results: All procedures were performed without complications. Mean age 64  12
years (range 43-75), 5 patients males. Diuretics were used in 6 out of 6 patients.
Systolic (1386 at 1M vs. 1508 at 1D and 1516 mmHg at B, p< 0.01), diastolic
(7310 at 1M vs.7912 at 1D and 8112 mmHg at B, p< 0.01) and mean (946 at
1M vs. 1027 at 1D and 1056 mmHg at B, p< 0.01) arterial pressure values, allpertension Therapies Including Renal Denervation B123
